Leerink lifts target to USD 388.00: Cencora stock sits 14.90 percent below its high

Published on 10/09/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Leerink lifted its target to USD 388.00 on October 7, 2026. Cencora stock costs EUR 286.95 on October 9, 2026 after EUR 286.65, plus 0.10 percent.

Key points in brief

Leerink Partners raised its Cencora target from USD 380.00 to USD 388.00 on October 7, 2026.
Fiscal third-quarter revenue reached USD 84.8 billion, up 5.00 percent year over year.
Cencora raised fiscal 2026 adjusted earnings-per-share guidance to USD 17.75-17.95.
Cencora stock was EUR 286.95 at Lang & Schwarz on October 9, 2026, plus 0.10 percent versus the prior close.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) was trading at EUR 286.95 at Lang & Schwarz on October 9, 2026, while its NYSE quote was USD 321.29 at 10:31 a.m. ET. On October 7, 2026, Leerink Partners raised its Cencora target from USD 380.00 to USD 388.00, leaving the NYSE price 14.90 percent below its USD 377.54 52-week high, according to MarketBeat.

Three milestones shape the story

On August 5, 2026, Cencora reported fiscal third-quarter revenue of USD 84.75 billion, up 5.10 percent year over year, and adjusted earnings per share of USD 4.48, according to Yahoo Finance. On September 2, 2026, Cencora announced the launch of cell and gene therapy enablement through its Accelerate Pharmacy Solutions, while the company says it operates in over 50 countries on its corporate page.Cencora On October 7, 2026, the Leerink target moved to USD 388.00 from USD 380.00 while the rating stayed Outperform, according to MarketBeat.

What does the guidance raise change?

Management lifted fiscal 2026 adjusted earnings-per-share guidance to USD 17.75-17.95 from USD 17.70-17.90, while consolidated operating income growth guidance rose to 13.00-14.00 percent, according to Benzinga. The company also repurchased USD 1.0 billion of shares during the quarter, supporting 12.00 percent adjusted earnings-per-share growth. The combination points to capital returns and operating execution carrying more weight than revenue growth alone, since quarterly revenue advanced 5.10 percent while adjusted operating income increased 17.00 percent.

Next report date is set

Cencora plans to release fiscal fourth-quarter 2026 results on November 4, 2026, before the NYSE opens, followed by an 8:30 a.m. ET conference call, according to Cencora.

Cencora stock holds near its NYSE midpoint

Cencora stock was trading at EUR 286.95 at Lang & Schwarz on October 9, 2026 at 4:29 p.m. CEST, plus 0.10 percent versus the prior close of EUR 286.65. The NYSE quote was USD 321.29 at 10:31 a.m. ET, against a USD 244.82 to USD 377.54 52-week range, and market capitalization was USD 62.5 billion as of October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.